Tenofovir (Viread): Research
- Efficacy of Tenofovir DF Monotherapy in Chronically HIV-1 Infected Antiretroviral Treatment-Naive Patients (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Retrospective Analysis of the Use of Tenofovir DF in a Private Practice (July 8, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- Determining the Relative Efficacy of Tenofovir DF Using Frequent Measurements of HIV-1 RNA During a Short Course of Monotherapy in Antiretroviral Drug Naive Individuals (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- More Uses for Tenofovir? (January 25, 2002)
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
- Tenofovir DF: A 24-Week Interim Analysis From a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
- Tenofovir DF 907 Study: Tenofovir as Intensification Agent (October 30, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO.com
- Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in HIV-Infected Adults (October 2001)
From Antimicrobial Agents and Chemotherapy
- Tenacious Tenofovir Struts its Stuff in a Virtual ICAAC (October 2001)
Highlights from the abstracts for ICAAC 2001.
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
- Report on FDA Antiviral Advisory Committee Discussion of Viread (October 2001)
Including descriptions of Gilead's clinical trials for the drug.
In GMHC Treatment Issues, from Gay Men's Health Crisis
On TheBodyPRO.com
- New Drugs in Development: Very Viread (Fall 2001)
A look at the drug's indications, resistance profile and some clinical trial results.
To read PDF, click here.
In CRIA Update, from AIDS Community Research Initiative of America
- Highlights From Retrovirus 2001: Tenofovir DF Study 902 (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (ddI), Tenofovir (TFV), and the Combination of ABC and ddI In Vitro (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- ICAAC and Lipodystrophy Conference Coverage on Tenofovir (Winter 2000/2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Tenofovir Disoproxil Fumarate for the Treatment of Antiretroviral-Experienced Patients. A Double Blind, Placebo-Controlled Study (September 18, 2000)
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Animal Models -- Interventions (July 10, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Tenofovir DF: A Promising Nucleotide Analog in Development (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- PMPA -- First Human Results (April 18, 1997)
From AIDS Treatment News
- PMPA: New Information (June 7, 1996)
In AIDS Treatment News, from AIDS Treatment News
- PMPA: Experimental Drug That Completely Protects Monkeys Exposed to SIV (November 20, 1995)
From U.S. Centers for Disease Control and Prevention
|
Advertisement
|
Email
Glossary
